Advancing evidence-generating medicine
Osmind’s research is helping to set new standards for mental health interventions and improve patient outcomes. See how we work with research partners to generate real-world evidence to accelerate advances in mental health care.
Selected research projects
A phase 2 trial with CLE-100 oral esketamine for patients with MDD and inadequate response to antidepressant during COVID-19 pandemic
Hagai et al. (2024). Oxford Ketamine Conference.
Osmind Announces 2024 Community Advisory Board: Leading Mental Health Clinicians
Considering New and Emerging Treatment Strategies for Depression: Beyond STAR*D and the Monoamines
McInnes and Marton (2024). Current Psychiatry Research and Reviews.
Embracing pragmatism for ketamine insurance coverage: Leveraging real-world evidence
McInnes, Marton, Qian (2024). Journal of Affective Disorders.
Machine Learning (ML) Algorithms for Prediction of Treatment Response to Ketamine Infusion Therapy (KIT)
Kane, Worley, McInnes (2023). American Society of Ketamine Physicians, Psychotherapists & Practitioners Annual Meeting.
Using a longitudinal model to predict outcomes to ketamine intravenous therapy for depression
Kane, Worley, McInnes (2023). American College of Neuropharmacology Annual Meeting.
Let's transform mental health together
Click here to learn more about our research or to discuss collaboration opportunities.
